Nanomedicine News RSS Feed - Nanomedicine

Nanotube Fibers Bridge Electrical Gaps in Scarred Heart Tissue

Nanotube Fibers Bridge Electrical Gaps in Scarred Heart Tissue

Researchers from Rice University and Texas Heart Institute are investigating the application of soft, pliable carbon nanotube fibers to fix electrical gaps in heart tissues damaged by cardiac arrhythmias, which affect over 4 million people in America every year. [More]
NanoViricides to Accelerate Program for Herpecide Drug Development

NanoViricides to Accelerate Program for Herpecide Drug Development

NanoViricides, Inc.,, a nanomedicine company developing anti-viral drugs, reports that it is accelerating its HerpeCide™ drug development program. [More]
Significant Advancement in Use of Photodynamic Therapy to Combat Ovarian Cancer in Laboratory Animals

Significant Advancement in Use of Photodynamic Therapy to Combat Ovarian Cancer in Laboratory Animals

Researchers at Oregon State University have made a significant advance in the use of photodynamic therapy to combat ovarian cancer in laboratory animals, using a combination of techniques that achieved complete cancer cell elimination with no regrowth of tumors. [More]
Lab-on-a-Disc Platform Combines Microfluidics and Raman Microscopy for Rapid Detection of Urinary Tract Infections

Lab-on-a-Disc Platform Combines Microfluidics and Raman Microscopy for Rapid Detection of Urinary Tract Infections

Urinary tract infections can quickly move from being a merely miserable experience to a life-threatening condition. Untreated cases may trigger sepsis, which occurs when the immune system, in an attempt to fight off the infection, inadvertently activates body-wide inflammation that can cause blood clots and leaky blood vessels. [More]
Senior Scientific Granted Additional US Patent for MRX Cancer Detection Technology Using Nanoparticles

Senior Scientific Granted Additional US Patent for MRX Cancer Detection Technology Using Nanoparticles

Manhattan Scientifics, Inc. announced today that its Senior Scientific, LLC unit, a nanobiotechnology company for the early detection and localization of cancer and other human diseases, has been granted an additional United States Patent for its MRX™ cancer detection technology. U.S. Patent No. US 9,095,270 B2 entitled "Detection, measurement, and imaging of cells such as cancer and other biologic substances using targeted nanoparticles and magnetic properties thereof." The patent provides a method as well as an apparatus for detecting and measuring cancer cells, using magnetic nanoparticles. [More]
Dramatic Effects of Nanoviricides for Treating Herpes Simplex Virus Infection Reproduced in Animal Model

Dramatic Effects of Nanoviricides for Treating Herpes Simplex Virus Infection Reproduced in Animal Model

NanoViricides, Inc., (the "Company"), a nanomedicine company developing anti-viral drugs, reports that the dramatic improvements in clinical symptoms associated with herpes simplex virus infection were reproduced in an animal model in a different laboratory. These studies were performed by TransPharm Preclinical Solutions ("TransPharm"), a pre-clinical services company in Jackson, MI. [More]
Nanosphere Achieves Record Revenues of $4.7 Million for Second Quarter 2015

Nanosphere Achieves Record Revenues of $4.7 Million for Second Quarter 2015

Nanosphere, Inc., a company enhancing medicine through targeted molecular diagnostics, today reported financial and operating results for the second quarter ended June 30, 2015. [More]
Antibacterial Nanofibres of Cellulose Acetate Loaded with Silver Could Promote Tissue Repair

Antibacterial Nanofibres of Cellulose Acetate Loaded with Silver Could Promote Tissue Repair

People with diabetes mellitus often suffer from impaired wound healing. Now, scientists in Egypt have developed antibacterial nanofibres of cellulose acetate loaded with silver that could be used in a new type of dressing to promote tissue repair. They reveal details of the new materials and their properties in the International Journal of Nanoparticles. [More]
Dicerna's Lipid Nanoparticle Therapy for Primary Hyperoxaluria Type 1 Granted EMA Orphan Drug Designation

Dicerna's Lipid Nanoparticle Therapy for Primary Hyperoxaluria Type 1 Granted EMA Orphan Drug Designation

Dicerna Pharmaceuticals, Inc., a leading developer of RNA interference (RNAi) therapeutics, today announced that the European Medicines Agency (EMA) granted Orphan Drug Designation to DCR-PH1, the company's therapeutic candidate for the treatment of primary hyperoxaluria type 1 (PH1). PH1 is a severe, rare, inherited disorder of the liver that often results in kidney failure and for which there are no approved therapies. [More]
Nanofabrication Techniques Could Help Develop Brain-Friendly Interfaces

Nanofabrication Techniques Could Help Develop Brain-Friendly Interfaces

Recent research published in the journal Microsystems & Nanoengineering could eventually change the way people living with prosthetics and spinal cord injury lead their lives. [More]